Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Drug Watch” Early Warnings Will Have Lasting Negative Effect, PhRMA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

A “Drug Watch” listing can do lasting damage to a brand’s reputation based on inadequate data, PhRMA Chief Medical Officer Antony says. The PhRMA exec uses an “extreme” example to highlight his point: imagine “someone reporting that they had early information that you may be a child molester.”

You may also be interested in...



FDA Track Record In Risk Communication Raised As Key Sentinel Concern

FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop

FDA Track Record In Risk Communication Raised As Key Sentinel Concern

FDA's ongoing challenges with effectively communicating the risks indicated by postmarket safety signals need to be resolved before the agency activates its Sentinel surveillance program, a number of participants said during a Dec. 16 FDA workshop

FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site

FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism

Related Content

Topics

UsernamePublicRestriction

Register

PS062502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel